Zydus gets USFDA nod to sell morphine sulfate tablets
Pharmaceuticals major Zydus Group has announced the receipt of an approval from the US Food and Drug Administration (USFDA) to sell chronic pain reliever morphine sulfate tablets.
“The product used in treatment of chronic pain or cancer related pain will be manufactured at Nesher Pharmaceuticals (USA) LLC, located at St Louis,” Cadila Healthcare, a part of Zydus group, said in a filing to the BSE.
A subsidiary of Zydus Pharmaceuticals Inc, Nesher has considerable expertise in niche therapies with development or products barrier, such as controlled release medications, it added.